Skip to content

Illumina’s CEO Says Increasing Access to Testing Has Lifted Sales

  • Company has benefited as pandemic boosts sequencing demand
  • Illumina also announced an expansion into long-read sequencing
Video player cover image
Illumina Benefiting From Increased Access to Tests: CEO

Illumina Inc.’s top executive said increasing reimbursement for genetic screening by insurers and the company’s lower prices have helped drive a surge in demand for its testing products.

“We’re seeing a lot of progress in the genomics market in terms of making tests more available,” Chief Executive Officer Francis deSouza said in a Bloomberg Television interview. “For instance, we’ve seen a massive increase in reimbursement for cancer patients to use genomic tests.”